Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.32 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2989773 | 0.96 | IRAK4 (0.32) | IRAK4ITGB3ITGB2ITGB1ITGAV | |
| SCHEMBL1649789 | 0.89 | — | — | |
| SCHEMBL2984521 | 0.89 | — | — | |
| SCHEMBL157216 | 0.89 | — | — | |
| SCHEMBL2999352 | 0.85 | — | — | |
| SCHEMBL4381020 | 0.85 | — | — | |
| SCHEMBL5026514 | 0.85 | — | — | |
| SCHEMBL5963378 | 0.82 | AR (0.35) | IRAK4CRBNPDCD1LG2CD274 | |
| SCHEMBL25255061 | 0.81 | ITGB1 (0.40) | IRAK4ITGB3ITGB2ITGB1ITGAV | |
| SCHEMBL29742940 | 0.81 | KMT2A (0.35) | CRBNOR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-53025573-A | — | — | None | — | — | JP | disclosed |
| EP-2970099-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014164905-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20100222349-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| US-20100184770-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-07-22 | — | — | US | disclosed |
| EP-2205585-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | Glaxo Group Limited (GB) | 2010-07-14 | — | — | EP | disclosed |
| EP-2091538-B1 | 4-BENZYL-1(2H)-PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-03-03 | — | — | EP | disclosed |
| EP-2091538-A2 | 4-BENZYL-L(2H)-PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009050204-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
| WO-2008074803-A2 | 4-BENZYL-L ( 2H) -PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| EP-1608619-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004094382-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-0293740-B1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED LACTAMS | BASF Aktiengesellschaft (DE) | 1992-12-02 | — | — | EP | disclosed |
| US-4874865-A | Preparation of substituted lactams | BASF AKTIENGESELLSCHAFT (DE) | 1989-10-17 | — | — | US | disclosed |
| EP-0293740-A2 | Process for the preparation of substituted lactams | BASF Aktiengesellschaft (DE) | 1988-12-07 | — | — | EP | disclosed |
| JP-S5325573-A | OPTICAL ACTIVE 6-OXO-PIPERIDINEETHANOLS AND THEIR PREPARATION | TEIJIN LTD | 1978-03-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184770-A1 | COMPOUNDS | CMA1, TSLP, IL5 | IRAK4 810/4885ITGB3 4507/4885ITGB2 3979/4885 |
| US-20100222349-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | IL5, HRH2, HRH1 | IRAK4 171/4885ITGB3 4494/4885ITGB2 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.